Skip to main content

West Pharmaceutical Services stock price and financials

  • WST · NYSE
  • Medical devices
  • Health Care Supplies
  • S&P 500
$416.42+1.24%Close 13 Nov 2026
EV / EBITDA
29.97
Beta · 1 year
0.65
Return · 1 year
+52.1%
52-week range$223.83 — $438.27

Share price close 16 Nov 2026

+9.1%1 monthHigh $417.90Low $383.91
$380$390$400$410$420Q3 FY2026 report filed 29 Oct 202623 Oct29 Oct4 Nov10 Nov16 Nov
+38.0%6 monthsHigh $417.90Low $303.93
$300$350$400$450Q2 FY2026 report filed 23 Jul 2026Q3 FY2026 report filed 29 Oct 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+51.9%year to dateHigh $417.90Low $230.95
$200$250$300$350$400$450Q4 FY2025 report filed 17 Feb 2026Q1 FY2026 report filed 23 Apr 2026Q2 FY2026 report filed 23 Jul 2026Q3 FY2026 report filed 29 Oct 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+59.9%1 yearHigh $417.90Low $230.95
$200$250$300$350$400$450Q4 FY2025 report filed 17 Feb 2026Q1 FY2026 report filed 23 Apr 2026Q2 FY2026 report filed 23 Jul 2026Q3 FY2026 report filed 29 Oct 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+20.8%3 yearsHigh $417.90Low $190.39
$100$200$300$400$500Q4 FY2023 report filed 20 Feb 2024Q1 FY2024 report filed 25 Apr 2024Q2 FY2024 report filed 25 Jul 2024Q3 FY2024 report filed 24 Oct 2024Q4 FY2024 report filed 18 Feb 2025Q1 FY2025 report filed 24 Apr 2025Q2 FY2025 report filed 24 Jul 2025Q3 FY2025 report filed 23 Oct 2025Q4 FY2025 report filed 17 Feb 2026Q1 FY2026 report filed 23 Apr 2026Q2 FY2026 report filed 23 Jul 2026Q3 FY2026 report filed 29 Oct 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+421%10 yearsHigh $469.01Low $78.61
$0$100$200$300$400$500Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

West Pharmaceutical Services reported revenue of $3.07 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 6.3% from fiscal 2024. Net income was $494 million and diluted earnings per share $6.79.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $875 million, up 8.7% from a year earlier.

Figures from West Pharmaceutical Services's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 29 Oct 2026.

Revenue FY2025
$3.07B+6.3%
Net income
$493.7M+0.2%
Diluted EPS
$6.79+1.5%
Gross margin
35.9%+1.4 pts
Free cash flow
$468.9M+69.6%
Net cash
$470.2M

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$1B$2B$3B$4BRevenue, FY16: $1.51BNet income, FY16: $143.6MFY16Revenue, FY17: $1.6BNet income, FY17: $150.7MFY17Revenue, FY18: $1.72BNet income, FY18: $206.9MFY18Revenue, FY19: $1.84BNet income, FY19: $241.7MFY19Revenue, FY20: $2.15BNet income, FY20: $346.2MFY20Revenue, FY21: $2.83BNet income, FY21: $661.8MFY21Revenue, FY22: $2.89BNet income, FY22: $585.9MFY22Revenue, FY23: $2.95BNet income, FY23: $593.4MFY23Revenue, FY24: $2.89BNet income, FY24: $492.7MFY24Revenue, FY25: $3.07BNet income, FY25: $493.7MFY25

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 29 Oct 2026 · Full results →

Revenue
$874.5M+8.7% on a year
Gross margin
39.7%+3.1 pts on a year
Operating income
$267.4M+59.5% on a year
Net income
$214.0M+52.9% on a year
Diluted EPS
$3.02+57.3% on a year
Free cash flow
$150.4M+12.3% on a year

Comparable companies All of Health Care →

West Pharmaceutical Services beside the other S&P 500 members in Health Care Supplies, then the largest in Health Care, by market value.

West Pharmaceutical Services and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
West Pharmaceutical ServicesWST—+1.2%+52.1%———
The Cooper CompaniesCOO$11.91B+0.7%−13.6%+4.7%13.5%20.9
Align TechnologyALGN$11.84B+0.8%+18.8%+4.4%11.8%24.1
Eli LillyLLY$1.37T+1.1%+41.8%+45.5%31.9%49.6
Johnson & JohnsonJNJ$686.1B+0.8%+47.0%+7.8%16.2%42.6
AbbVieABBV$525.9B+0.2%+26.5%+10.7%15.7%51.1
AmgenAMGN$253.8B−0.3%+38.5%+8.2%24.1%27.0

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%20%40%60%35.9%19.0%16.1%FY16FY19FY22FY25

West Pharmaceutical Services revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

West Pharmaceutical Services revenue by segment, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
Proprietary Products$2.32B$2.41B+3.9%$2.40B−0.4%$2.33B−2.6%$2.49B+6.8%
West Vantage$514.7M$480.4M−6.7%$552.5M+15.0%$558.7M+1.1%$582.0M+4.2%
Total revenue$2.83B$2.89B$2.95B$2.89B$3.07B

By region

West Pharmaceutical Services revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$1.20B$1.29B+7.4%$1.24B−3.7%$1.23B−0.6%$1.33B+8.0%
Other European countries$341.3M$359.2M+5.2%$388.1M+8.0%$385.5M−0.7%$451.0M+17.0%
Germany$474.3M$398.7M−15.9%$406.1M+1.9%$372.5M−8.3%$380.3M+2.1%
Other$357.4M$364.3M+1.9%$348.5M−4.3%$339.0M−2.7%$353.3M+4.2%
Ireland$247.6M$240.3M−2.9%$285.7M+18.9%$323.2M+13.1%$333.3M+3.1%
FR$213.0M$237.9M+11.7%$282.9M+18.9%$242.2M−14.4%$226.6M−6.4%
Total revenue$2.83B$2.89B$2.95B$2.89B$3.07B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

West Pharmaceutical Services income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$1.51B$1.60B$1.72B$1.84B$2.15B$2.83B$2.89B$2.95B$2.89B$3.07B
Revenue growth+7.8%+6.0%+7.4%+7.1%+16.7%+31.9%+2.0%+2.2%−1.9%+6.3%
Gross profit$501.4M$512.9M$545.4M$605.7M$767.8M$1.18B$1.14B$1.13B$998.5M$1.10B
Operating income$195.2M$225.8M$240.3M$296.6M$406.9M$752.3M$734.0M$676.0M$569.9M$584.9M
Net income$143.6M$150.7M$206.9M$241.7M$346.2M$661.8M$585.9M$593.4M$492.7M$493.7M
Diluted EPS$1.91$1.99$2.74$3.21$4.57$8.67$7.73$7.88$6.69$6.79
Gross margin33.2%32.1%31.8%32.9%35.8%41.5%39.4%38.3%34.5%35.9%
Operating margin12.9%14.1%14.0%16.1%19.0%26.6%25.4%22.9%19.7%19.0%
Net margin9.5%9.4%12.0%13.1%16.1%23.4%20.3%20.1%17.0%16.1%

Cash flow

West Pharmaceutical Services cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$219.4M$263.3M$288.6M$367.2M$472.5M$584.0M$724.0M$776.5M$653.4M$754.8M
Capital expenditure$170.2M$130.8M$104.7M$126.4M$174.4M$253.4M$284.6M$362.0M$377.0M$285.9M
Free cash flow$49.20M$132.5M$183.9M$240.8M$298.1M$330.6M$439.4M$414.5M$276.4M$468.9M

Balance sheet and shares

West Pharmaceutical Services balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$203.0M$235.9M$337.4M$439.1M$615.5M$762.6M$894.3M$853.9M$484.6M$791.3M
Total debt$228.6M$197.0M$196.1M$329.3M$325.7M$325.3M$317.9M$309.0M$302.3M$321.1M
Shareholders' equity$1.12B$1.28B$1.40B$1.57B$1.85B$2.34B$2.68B$2.88B$2.68B$3.18B
Diluted shares75.0M75.8M75.4M75.4M75.8M76.3M75.8M75.3M73.7M72.7M
Dividends per share$0.50$0.54$0.58$0.62$0.66$0.70$0.74$0.78$0.82$0.86

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

West Pharmaceutical Services quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$748.8M$698.0M$766.5M$804.6M$805.0M$844.9M$872.3M$874.5M
Revenue, year on year+2.3%+0.4%+9.2%+7.7%+7.5%+21.0%+13.8%+8.7%
Gross margin36.5%33.2%35.7%36.6%37.8%35.1%37.7%39.7%
Operating income$159.6M$107.0M$153.7M$167.6M$156.6M$177.1M$179.1M$267.4M
Net income$130.1M$89.80M$131.8M$140.0M$132.1M$138.8M$154.0M$214.0M
Diluted EPS$1.77$1.23$1.82$1.92$1.82$1.92$2.15$3.02
Free cash flow$85.20M$58.10M$101.9M$133.9M$175.0M$47.20M$80.80M$150.4M

Operating KPIs

The operating figures West Pharmaceutical Services reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

West Pharmaceutical Services operating KPIs
KPILatestPeriodChange on a yearRecent periods
Proprietary Products revenue$728.8Mquarter to 30 Sep 2026up 12.6%
West Vantage revenue$145.7Mquarter to 30 Sep 2026down 7.3%
United States revenue$1.3Bfiscal year to 31 Dec 2025up 8.0%
Germany revenue$380.3Mfiscal year to 31 Dec 2025up 2.1%
Ireland revenue$333.3Mfiscal year to 31 Dec 2025up 3.1%
FR revenue$226.6Mfiscal year to 31 Dec 2025down 6.4%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was West Pharmaceutical Services's revenue in fiscal 2025?

$3.07 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was West Pharmaceutical Services's net income in fiscal 2025?

$494 million for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were West Pharmaceutical Services's diluted earnings per share in fiscal 2025?

$6.79 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is West Pharmaceutical Services's gross margin?

35.9% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is West Pharmaceutical Services's operating margin?

19.0% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did West Pharmaceutical Services generate in fiscal 2025?

$469 million for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does West Pharmaceutical Services's revenue come from?

In fiscal 2025, by segment: Proprietary Products $2.49B (81%), West Vantage $582.0M (19%), out of $3.07B in all, as stated in its annual report.

In the terminal

Twenty years of West Pharmaceutical Services's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans